Finallmente, algo novo da Big Pharma para hipertensão - o aliskiren - da Novartis,nome comercial Tekturna, aprovado nos Estados Unidos. Trata-se de um inibidor da renina, o primeiro produto desse grupo. Agora, é verificar o quanto adicionará ao tratamento atual e, evidentemente o custo. Abaixo uma descrição do produto.
Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US
Mar 5 2007, 8:20 PM EST PRNEWSWIRE
EAST HANOVER, N.J., March 6 /PRNewswire/ -- Novartis announced today that the United States has become the first country in the world to approve Tekturna(R) (aliskiren) tablets, the first new type of medicine in more than a decade for treating high blood pressure -- a condition estimated to affect nearly one billion people worldwide and remains uncontrolled in nearly 70% of patients.
The Food and Drug Administration (FDA) issued the approval for Tekturna as the first in a new class of drugs called direct renin inhibitors. A once-daily oral therapy, Tekturna acts by targeting renin -- an enzyme responsible for triggering a process that can contribute to high blood pressure. This condition is a leading contributor to cardiovascular disease, considered the world's leading cause of death. Tekturna received FDA approval for treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. The use of Tekturna with maximal doses of ACE inhibitors has not been adequately studied. Tekturna is expected to be available in March in pharmacies as 150 mg and 300 mg tablets. "Renin angiotensin system activity contributes to many of the complications associated with high blood pressure," said Marc A. Pfeffer, M.D., PhD, Professor of Medicine, Harvard Medical School and Cardiologist, at Brigham & Women's Hospital. "By inhibiting this important system at its origin, renin production, a direct renin inhibitor, such as Tekturna, offers an exciting therapeutic option for treating hypertension." In an extensive clinical trial program involving more than 6,400 patients, Tekturna provided significant blood pressure reductions for a full 24 hours. Furthermore, Tekturna provided added efficacy when used in combination with other commonly used blood pressure medications. In clinical trials, the approved doses of Tekturna were generally well tolerated and the most common side effect experienced by more patients taking Tekturna than patients taking a sugar pill was diarrhea. Other less common reactions to Tekturna include cough and rash. Tekturna should be discontinued as soon as pregnancy is detected as it may harm an unborn baby, causing injury and even death. Women who plan to become pregnant should talk to their doctor about other treatment options before taking Tekturna. Angioedema has been rarely reported in patients taking Tekturna. "Many patients require two or more medicines to control their blood pressure. As a new treatment approach, Tekturna has the potential to help these patients manage their disease," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "Tekturna demonstrates our commitment to developing innovative medicines to help the millions of patients suffering from high blood pressure." Novartis is committed to conducting a large outcome trial program to evaluate the long-term effects of Tekturna and direct renin inhibition. Tekturna was developed in collaboration with Speedel
Mar 5 2007, 8:20 PM EST PRNEWSWIRE
EAST HANOVER, N.J., March 6 /PRNewswire/ -- Novartis announced today that the United States has become the first country in the world to approve Tekturna(R) (aliskiren) tablets, the first new type of medicine in more than a decade for treating high blood pressure -- a condition estimated to affect nearly one billion people worldwide and remains uncontrolled in nearly 70% of patients.
The Food and Drug Administration (FDA) issued the approval for Tekturna as the first in a new class of drugs called direct renin inhibitors. A once-daily oral therapy, Tekturna acts by targeting renin -- an enzyme responsible for triggering a process that can contribute to high blood pressure. This condition is a leading contributor to cardiovascular disease, considered the world's leading cause of death. Tekturna received FDA approval for treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. The use of Tekturna with maximal doses of ACE inhibitors has not been adequately studied. Tekturna is expected to be available in March in pharmacies as 150 mg and 300 mg tablets. "Renin angiotensin system activity contributes to many of the complications associated with high blood pressure," said Marc A. Pfeffer, M.D., PhD, Professor of Medicine, Harvard Medical School and Cardiologist, at Brigham & Women's Hospital. "By inhibiting this important system at its origin, renin production, a direct renin inhibitor, such as Tekturna, offers an exciting therapeutic option for treating hypertension." In an extensive clinical trial program involving more than 6,400 patients, Tekturna provided significant blood pressure reductions for a full 24 hours. Furthermore, Tekturna provided added efficacy when used in combination with other commonly used blood pressure medications. In clinical trials, the approved doses of Tekturna were generally well tolerated and the most common side effect experienced by more patients taking Tekturna than patients taking a sugar pill was diarrhea. Other less common reactions to Tekturna include cough and rash. Tekturna should be discontinued as soon as pregnancy is detected as it may harm an unborn baby, causing injury and even death. Women who plan to become pregnant should talk to their doctor about other treatment options before taking Tekturna. Angioedema has been rarely reported in patients taking Tekturna. "Many patients require two or more medicines to control their blood pressure. As a new treatment approach, Tekturna has the potential to help these patients manage their disease," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "Tekturna demonstrates our commitment to developing innovative medicines to help the millions of patients suffering from high blood pressure." Novartis is committed to conducting a large outcome trial program to evaluate the long-term effects of Tekturna and direct renin inhibition. Tekturna was developed in collaboration with Speedel
Nenhum comentário:
Postar um comentário